In accordance with the National Cancer Institute Policies and Guidelines Relating to the Cancer Center Support Grant, this core group of research nurses and data managers provides central management and oversight functions for coordinating, facilitating and reporting on the cancer clinical trials of the Cancer Center. Of primary importance is the identification and support of phase I and II trials emanating from the work generated by Cancer Center affiliated physician-scientists. Support is prioritized to ensure the initiation and completion of innovative, feasibility, or proof-of-principle clinical trials originating from the Center's Programs and of highest priority to the Center. These include any kind of clinical translational research culminating in the initial early-phase testing of a candidate agent or device for the diagnosis, prevention, detection, or treatment of cancer. The ultimate goal of supporting such research efforts is to foster the translation of feasibility/phase I studies into future grant applications or into phase II and phase III studies supported by NCI or industry. Oversight of this group is provided by the Associate Director of Clinical Research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
United States
Zip Code
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Parihar, Vipan K; Allen, Barrett D; Tran, Katherine K et al. (2015) Targeted overexpression of mitochondrial catalase prevents radiation-induced cognitive dysfunction. Antioxid Redox Signal 22:78-91
Stockler, Martin R; Hilpert, Felix; Friedlander, Michael et al. (2014) Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol 32:1309-16
Sun, Peng; Watanabe, Kazuhide; Fallahi, Magid et al. (2014) Pygo2 regulates ?-catenin-induced activation of hair follicle stem/progenitor cells and skin hyperplasia. Proc Natl Acad Sci U S A 111:10215-20
Lackford, Brad; Yao, Chengguo; Charles, Georgette M et al. (2014) Fip1 regulates mRNA alternative polyadenylation to promote stem cell self-renewal. EMBO J 33:878-89
Balu, Mihaela; Kelly, Kristen M; Zachary, Christopher B et al. (2014) Distinguishing between benign and malignant melanocytic nevi by in vivo multiphoton microscopy. Cancer Res 74:2688-97
Yonova, Ivelina M; Osborne, Charlotte A; Morrissette, Naomi S et al. (2014) Diaryl and heteroaryl sulfides: synthesis via sulfenyl chlorides and evaluation as selective anti-breast-cancer agents. J Org Chem 79:1947-53
Watanabe, K; Fallahi, M; Dai, X (2014) Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice. Oncogene 33:632-42
Muto, Akihiko; Ikeda, Shingo; Lopez-Burks, Martha E et al. (2014) Nipbl and mediator cooperatively regulate gene expression to control limb development. PLoS Genet 10:e1004671
Kim, Monica Y; Li, David Jiang; Pham, Long K et al. (2014) Microfabrication of High-Resolution Porous Membranes for Cell Culture. J Memb Sci 452:460-469

Showing the most recent 10 out of 289 publications